Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 147

1.

Excessive toxicity of the high dose thiotepa and etoposide regimen when combined with radiation: Long-term autologous transplantation experience in follicular and mantle cell lymphoma.

Fenske TS, Kahl BS, Eickhoff J, Mitchell TL, Smith EP, Atkinson E, McCoy AG, Eckstein L, Flynn B, McMannes J, Howard S, Longo WL.

Leuk Lymphoma. 2005 Oct;46(10):1441-8.

PMID:
16194889
2.

A novel preparative regimen for autologous transplant in non-Hodgkin's lymphoma: long-term experience with etoposide and thiotepa.

McCoy AG, Smith EP, Atkinson ME, Baranski B, Kahl BS, Juckett M, Mitchell T, Gangnon R, Longo WL.

Bone Marrow Transplant. 2004 Jan;33(1):19-24.

PMID:
14704653
3.

High-dose therapy and autologous hematopoietic-cell transplantation for follicular lymphoma beyond first remission: the Stanford University experience.

Cao TM, Horning S, Negrin RS, Hu WW, Johnston LJ, Taylor TL, Shizuru JA, Hoppe RT, Brown BW, Blume KG, Stockerl-Goldstein KE.

Biol Blood Marrow Transplant. 2001;7(5):294-301.

PMID:
11400952
4.

Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma.

Hänel M, Kröger N, Sonnenberg S, Bornhäuser M, Krüger W, Kroschinsky F, Hänel A, Metzner B, Birkmann J, Schmid B, Hoffknecht MM, Fiedler F, Ehninger G, Zander AR.

Ann Hematol. 2002 Feb;81(2):96-102. Epub 2002 Jan 10.

PMID:
11907790
5.

Autologous stem cell transplantation for follicular lymphoma: no benefit for early transplant?

Seyfarth B, Kuse R, Sonnen R, Glass B, Schmitz N, Dreger P.

Ann Hematol. 2001 Jul;80(7):398-405.

PMID:
11529465
6.

High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation in patients with lymphoma -- a retrospective evaluation.

Demirer T, Ayli M, Fen T, Ozcan M, Arat M, Buyukberber S, Arslan O, Gurman G, Akan H, Ilhan O.

Bone Marrow Transplant. 2004 Nov;34(9):781-6.

PMID:
15354206
7.

Efficacy of high-dose therapy and autologous hematopoietic stem cell transplantation for non-Hodgkin's lymphoma in adults 60 years of age and older.

Gopal AK, Gooley TA, Golden JB, Maloney DG, Bensinger WI, Petersdorf SH, Appelbaum FR, Press OW.

Bone Marrow Transplant. 2001 Mar;27(6):593-9.

9.

[Total body irradiation etoposide followed by autologous hematopoietic stem cell transplantion for non-Hodgkin's lymphoma].

Shi Y, Lei Y, Zhou S.

Zhonghua Yi Xue Za Zhi. 1998 Sep;78(9):658-61. Chinese.

PMID:
11038787
10.
11.

High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma.

Illerhaus G, Marks R, Ihorst G, Guttenberger R, Ostertag C, Derigs G, Frickhofen N, Feuerhake F, Volk B, Finke J.

J Clin Oncol. 2006 Aug 20;24(24):3865-70. Epub 2006 Jul 24.

PMID:
16864853
12.

Cardiovascular toxicity is increased, but manageable, during high-dose chemotherapy and autologous peripheral blood stem cell transplantation for patients aged 60 years and older.

Mileshkin LR, Seymour JF, Wolf MM, Gates P, Januszewicz EH, Joyce P, Prince HM.

Leuk Lymphoma. 2005 Nov;46(11):1575-9.

PMID:
16236612
13.

Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma.

Benekli M, Smiley SL, Younis T, Czuczman MS, Hernandez-Ilizaliturri F, Bambach B, Battiwalla M, Padmanabhan S, McCarthy PL Jr, Hahn T.

Bone Marrow Transplant. 2008 Apr;41(7):613-9. Epub 2007 Dec 10.

PMID:
18071290
14.
15.
16.

Effect of rituximab on the long-term outcome after high-dose therapy for relapsed B-cell non-Hodgkin's lymphoma.

Hess G, Flohr T, Kolbe K, Bonn S, Schuler M, Derigs HG, Huber C.

Ann Hematol. 2006 Nov;85(11):769-79. Epub 2006 Aug 1.

PMID:
16896912
17.

Time-dependent effect of non-Hodgkin's lymphoma grade on disease-free survival of relapsed/refractory patients treated with high-dose chemotherapy plus autotransplantation.

Fu P, van Heeckeren WJ, Wadhwa PD, Bajor DJ, Creger RJ, Xu Z, Cooper BW, Laughlin MJ, Gerson SL, Koç ON, Lazarus HM.

Contemp Clin Trials. 2008 Mar;29(2):157-64. Epub 2007 Jul 19.

PMID:
17707140
18.

Phase II study of concomitant chemoradiotherapy in bulky refractory or chemoresistant relapsed lymphomas.

Girinsky T, Lapusan S, Ribrag V, Koscielny S, Ferme C, Carde P.

Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):476-9.

PMID:
15667970
19.

Involved-field radiotherapy before high-dose therapy and autologous stem-cell rescue in diffuse large-cell lymphoma: long-term disease control and toxicity.

Hoppe BS, Moskowitz CH, Filippa DA, Moskowitz CS, Kewalramani T, Zelenetz AD, Yahalom J.

J Clin Oncol. 2008 Apr 10;26(11):1858-64. doi: 10.1200/JCO.2007.15.4773. Epub 2008 Mar 10. Erratum in: J Clin Oncol. 2008 Aug 20;26(24):4053. Zelenet, Andrew D [corrected to Zelenetz, Andrew D].

PMID:
18332466
20.

High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis.

Gopal AK, Gooley TA, Maloney DG, Petersdorf SH, Eary JF, Rajendran JG, Bush SA, Durack LD, Golden J, Martin PJ, Matthews DC, Appelbaum FR, Bernstein ID, Press OW.

Blood. 2003 Oct 1;102(7):2351-7. Epub 2003 May 15.

Supplemental Content

Support Center